WO2011065420A1 - 6-置換-1-メチル-1h-ベンズイミダゾール誘導体の製造法及びその製造中間体 - Google Patents
6-置換-1-メチル-1h-ベンズイミダゾール誘導体の製造法及びその製造中間体 Download PDFInfo
- Publication number
- WO2011065420A1 WO2011065420A1 PCT/JP2010/071014 JP2010071014W WO2011065420A1 WO 2011065420 A1 WO2011065420 A1 WO 2011065420A1 JP 2010071014 W JP2010071014 W JP 2010071014W WO 2011065420 A1 WO2011065420 A1 WO 2011065420A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- hydrogen atom
- acid
- substituted
- methyl
- protecting group
- Prior art date
Links
- 0 C*c1cc(Oc(cc2C)cc(C)c2N)ccc1NC(C*c1ccc(CC(C(N2)=O)SC2=O)cc1)=O Chemical compound C*c1cc(Oc(cc2C)cc(C)c2N)ccc1NC(C*c1ccc(CC(C(N2)=O)SC2=O)cc1)=O 0.000 description 3
- RPFXLRPVGYTXNL-UHFFFAOYSA-N Cc1cc(Oc(cc2NC)ccc2N)cc(C)c1N Chemical compound Cc1cc(Oc(cc2NC)ccc2N)cc(C)c1N RPFXLRPVGYTXNL-UHFFFAOYSA-N 0.000 description 3
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C213/00—Preparation of compounds containing amino and hydroxy, amino and etherified hydroxy or amino and esterified hydroxy groups bound to the same carbon skeleton
- C07C213/02—Preparation of compounds containing amino and hydroxy, amino and etherified hydroxy or amino and esterified hydroxy groups bound to the same carbon skeleton by reactions involving the formation of amino groups from compounds containing hydroxy groups or etherified or esterified hydroxy groups
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A61K31/427—Thiazoles not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C217/00—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton
- C07C217/78—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having amino groups and etherified hydroxy groups bound to carbon atoms of six-membered aromatic rings of the same carbon skeleton
- C07C217/80—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having amino groups and etherified hydroxy groups bound to carbon atoms of six-membered aromatic rings of the same carbon skeleton having amino groups and etherified hydroxy groups bound to carbon atoms of non-condensed six-membered aromatic rings
- C07C217/82—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having amino groups and etherified hydroxy groups bound to carbon atoms of six-membered aromatic rings of the same carbon skeleton having amino groups and etherified hydroxy groups bound to carbon atoms of non-condensed six-membered aromatic rings of the same non-condensed six-membered aromatic ring
- C07C217/90—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having amino groups and etherified hydroxy groups bound to carbon atoms of six-membered aromatic rings of the same carbon skeleton having amino groups and etherified hydroxy groups bound to carbon atoms of non-condensed six-membered aromatic rings of the same non-condensed six-membered aromatic ring the oxygen atom of at least one of the etherified hydroxy groups being further bound to a carbon atom of a six-membered aromatic ring, e.g. amino-diphenylethers
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
- C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
- C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D277/32—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D277/34—Oxygen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
- Y02P20/00—Technologies relating to chemical industry
- Y02P20/50—Improvements relating to the production of bulk chemicals
- Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups
Definitions
- the present invention relates to a method for producing 6-substituted-1-methyl-1H-benzimidazole derivatives having an excellent ability to activate peroxisome proliferator-activated receptor (PPAR) ⁇ and having an excellent anticancer activity, and their It relates to a production intermediate.
- PPAR peroxisome proliferator-activated receptor
- 6-Substituted-1-methyl-1H-benzimidazole derivatives have excellent insulin resistance improving action, hypoglycemic action, anti-inflammatory action, aldose reductase inhibitory action, 5-lipoxygenase inhibitory action, lipid peroxide production inhibitory action It is known to have an action, a PPAR activation action, a leukotriene antagonism, an adipogenesis promoting action, a cancer cell growth inhibitory action, and a calcium antagonism (Patent Documents 1, 2, 3, and 4).
- 6-substituted-1-methyl-1H-benzimidazole derivatives are obtained by reacting 4-substituted-N 2 -methylbenzene-1,2-diamines with a protected N-methylamino group with the corresponding carboxylic acid derivatives. It is known that it can be synthesized by condensation reaction, subsequent deprotection, and intramolecular dehydration reaction (Patent Documents 2, 3, 4, 5, and 6).
- Japanese Patent No. 2976885 U.S. Patent No. 5886014, European Patent No. 745600
- Japanese Patent No. 3488099 U.S. Pat. No. 6,432,993, European Patent No. 1022272
- JP 2000-351777 International Publication No. 00/61582 pamphlet
- Japanese Patent No. 4197387 U.S. Pat. No. 6,562,849, European Patent Application No. 1167366
- JP 2001-97954 A JP 2001-72671 A US Pat. No. 6,525,220, European Patent No. 119101
- JP 2006-225382 A US Patent Application Publication No. 2008/0103185, European Patent Application Publication No. 1894929)
- Japanese Patent Laid-Open No. 2006-124375 US Patent Application Publication No. 2009/0023929, European Patent Application Publication No. 1798216
- the present inventors have provided a method for producing a high-purity 4-substituted-N 2 -methylbenzene-1,2-diamine derivative in high yield without protecting the N-methylamino group, and 4-substituted-N 2 -A method of selectively reacting one amino group of methylbenzene-1, 2-diamine derivative with a carboxylic acid derivative, and further, by intramolecular dehydration reaction of the obtained amide compound, 6-substituted-1-
- the present inventors have completed the present invention by discovering methods for obtaining methyl-1H-benzimidazole derivatives and novel intermediates in these production methods.
- R 1 represents a hydrogen atom, a C 1 -C 4 alkyl group, or a protecting group for a nitrogen atom
- R 2 represents a protecting group for a hydrogen atom or a nitrogen atom.
- R 3 represents a hydrogen atom or a C 1 -C 4 alkyl group.
- R 1 represents a hydrogen atom, a C 1 -C 4 alkyl group, or a protecting group for a nitrogen atom
- R 2 represents a protecting group for a hydrogen atom or a nitrogen atom
- R 1 represents a hydrogen atom, a C 1 -C 4 alkyl group, or a protecting group for a nitrogen atom
- R 2 represents a protecting group for a hydrogen atom or a nitrogen atom.
- R 1 represents a hydrogen atom, a C 1 -C 4 alkyl group, or a protecting group for a nitrogen atom
- R 2 represents a protecting group for a hydrogen atom or a nitrogen atom
- the following general formula (II) characterized by reacting with an acid chloride or a mixed acid anhydride:
- R 1 represents a hydrogen atom, a C 1 -C 4 alkyl group, or a protecting group for a nitrogen atom
- R 2 represents a protecting group for a hydrogen atom or a nitrogen atom.
- R 1 represents a hydrogen atom, a C 1 -C 4 alkyl group, or a protecting group for a nitrogen atom
- R 2 represents a protecting group for a hydrogen atom or a nitrogen atom.
- the following general formula (I) is obtained by reducing a 5-substituted-N-methyl-2-nitroaniline derivative represented by the following formula:
- R 1 represents a hydrogen atom, a C 1 -C 4 alkyl group, or a protecting group for a nitrogen atom
- R 2 represents a protecting group for a hydrogen atom or a nitrogen atom.
- R 1 represents a hydrogen atom, a C 1 -C 4 alkyl group, or a protecting group for a nitrogen atom
- R 2 represents a protecting group for a hydrogen atom or a nitrogen atom.
- the following general formula (I) is reduced by hydrogenation of a 5-substituted-N-methyl-2-nitroaniline derivative represented by the following formula:
- R 1 represents a hydrogen atom, a C 1 -C 4 alkyl group, or a protecting group for a nitrogen atom
- R 2 represents a protecting group for a hydrogen atom or a nitrogen atom.
- R 1 represents a hydrogen atom, a C 1 -C 4 alkyl group, or a protecting group for a nitrogen atom
- R 2 represents a protecting group for a hydrogen atom or a nitrogen atom
- R 3 represents a hydrogen atom or a C 1 -C 4 alkyl group
- the C 1 -C 4 alkyl group is a linear or branched alkyl group having 1 to 4 carbon atoms, such as a methyl group, an ethyl group, a propyl group, a butyl group, an isopropyl group, an isobutyl group. , S-butyl group, or t-butyl group.
- they are a methyl group, an ethyl group, a propyl group, a butyl group, or an isobutyl group. More preferably, it is a methyl group.
- aliphatic acyl group examples include unsaturated alkylcarbonyl groups such as acryloyl, propioloyl, methacryloyl, crotonoyl, isocrotonoyl, and (E) -2-methyl-2-butenoyl.
- aromatic acyl group examples include a nitrated arylcarbonyl group such as 4-nitrobenzoyl and 2-nitrobenzoyl, a lower alkoxycarbonylated arylcarbonyl group such as 2- (methoxycarbonyl) benzoyl, 4 An arylated arylcarbonyl group such as phenylbenzoyl.
- silyl group examples include tri-lower alkylsilyl groups such as trimethylsilyl, triethylsilyl, isopropyldimethylsilyl, t-butyldimethylsilyl, methyldiisopropylsilyl, methyldi-t-butylsilyl, triisopropylsilyl; diphenylmethylsilyl, diphenylbutyl A tri-lower alkylsilyl group substituted with 1 to 2 aryl groups such as silyl, diphenylisopropylsilyl and phenyldiisopropylsilyl. *
- alkoxycarbonyl group examples include a lower alkoxycarbonyl group having 1 to 6 carbon atoms such as methoxycarbonyl, ethoxycarbonyl, propoxycarbonyl, butoxycarbonyl, s-butoxycarbonyl, t-butoxycarbonyl, and isobutoxycarbonyl.
- alkenyloxycarbonyl group examples include lower alkenyloxycarbonyl having 3 to 6 carbon atoms such as allyloxycarbonyl and methallyloxycarbonyl.
- aralkyl group examples include 4-methylbenzyl, 2,4,6-trimethylbenzyl, 3,4,5-trimethylbenzyl, 4-methoxybenzyl, 2-nitrobenzyl, 4-nitrobenzyl, 4-chlorobenzyl, An aralkyl group in which the aryl ring is substituted with 1 to 3 lower alkyl, lower alkoxy, nitro, halogen or cyano groups, such as 4-bromobenzyl and 4-cyanobenzyl.
- an alkoxycarbonyl group is preferable, and a t-butoxycarbonyl group is particularly preferable.
- a salt or a pharmacologically acceptable salt means a 4-substituted-N 2 -methylbenzene-1,2-diamine derivative represented by the general formula (I) of the present invention and a general formula (IV) table.
- the 6-substituted-1-methyl-1H-benzimidazole derivative having a basic group such as an amino group can be converted into a salt by reacting with an acid, the salt is shown.
- inorganic acid salts such as hydrochloride, hydrobromide, hydroiodide, sulfate, nitrate, phosphate, or borate; methanesulfonate, ethanesulfonate, benzenesulfonate Sulfonates such as salts, p-toluenesulfonate, or camphorsulfonate; formate, acetate, propionate, oxalate, hydroxyacetate, citrate, tartrate, succinate, maleate Organic carboxylate such as acid salt, benzoate, salicylate, fumarate or phthalate, etc., preferably hydrochloride, hydrobromide, sulfate, phosphate, methanesulfone Acid salt, benzenesulfonate, p-toluenesulfonate, oxalate, or tartrate, and more preferably hydrochloride, hydrobromide, sulfate,
- Specific compounds of the general formulas (I) and (II) of the present invention can include the compounds described in the following table.
- the compounds represented by the general formulas (I) and (II) of the present invention are: It is not limited to these compounds.
- FIG. 11 is a powder X-ray diffraction pattern of the crystals obtained in Example 11.
- the vertical axis in the figure indicates the diffraction intensity in units of count / second (cps), and the horizontal axis indicates the value of the diffraction angle 2 ⁇ .
- R 1 , R 2 and R 3 are as defined above.
- the method of the present invention is a novel 4-substituted-N 2 -methylbenzene-1,2-diamine derivative obtained by reducing the nitro group of 5-substituted-N-methyl-2-nitroaniline derivative (III) by catalytic hydrogenation.
- a first step of producing (I) or a salt thereof; 4-substituted-N 2 -methylbenzene-1,2-diamine derivative (I) or a salt thereof and 4-[(2,4-dioxothiazolidin-5-yl) methyl] phenoxyacetic acid are used as a condensing agent.
- the 5-substituted-N-methyl-2-nitroaniline derivative (III) as a starting material is a known compound disclosed in International Publication No. 2006/035585, and can be obtained by the production method described in WO 2006/035585. It can be easily synthesized.
- the catalyst used in this step is not particularly limited as long as it is usually used for hydrogenation.
- examples of such a catalyst include palladium carbon catalyst, palladium hydroxide, platinum carbon catalyst, or Raney nickel, preferably palladium carbon catalyst, palladium hydroxide, or platinum carbon catalyst, and more preferably palladium carbon catalyst. Is mentioned. *
- an antioxidant may be added to the reaction system to prevent this oxidation.
- the antioxidant to be used is not particularly limited as long as it does not affect the reaction and does not react with raw materials, product organisms, solvents, etc., but preferably 2,6-di- t-Butyl-4-methylphenol is used.
- the amount of the antioxidant used is not particularly limited, but is usually 0.0001 equivalent to 1 equivalent, preferably 0.001 based on the 5-substituted-N-methyl-2-nitroaniline derivative (III) used. Equivalent to 0.1 equivalent is used.
- the hydrogen pressure in this step is not particularly limited, but is usually 1 to 30 atm, preferably 1 to 10 atm, and more preferably 1 to 5 atm.
- the reaction temperature in this step is not particularly limited, but is usually ⁇ 20 ° C. to 200 ° C., preferably ⁇ 20 ° C. to 120 ° C., more preferably 0 ° C. to 80 ° C. *
- the reaction time for this step is the reaction conditions such as the starting 5-substituted-N-methyl-2-nitroanilines (III) itself, the solvent used, concentration, equivalent number of catalyst used, hydrogen pressure, reaction temperature, etc. Depending on the case, it is usually 5 minutes to 5 days, preferably 10 minutes to 2 days, and more preferably 30 minutes to 24 hours.
- the catalyst is removed by filtration or the like, and the desired 4-substituted-N 2 -methylbenzene-1,2-diamine derivative (I) solution can be obtained.
- the obtained solution of 4-substituted-N 2 -methylbenzene-1,2-diamine derivative (I) is used as it is in the next step when the solvent does not react or inhibit the reaction under the reaction conditions in the next step. Also good. Further, the 4-substituted-N 2 -methylbenzene-1,2-diamine derivative (I) may be isolated by concentration.
- the obtained 4-substituted-N 2 -methylbenzene-1,2-diamine derivative (I) when it is crystallized as a crystal, it can be isolated by an operation such as filtration.
- the isolated 4-substituted-N 2 -methylbenzene-1,2-diamine derivative (I) can be further purified by ordinary purification operations such as recrystallization, distillation, column chromatography and the like.
- the isolated 4-substituted-N 2 -methylbenzene-1,2-diamine derivative (I) may be dried and used in the next step, or may be used in the next step without drying.
- the 4-substituted-N 2 -methylbenzene-1,2-diamine derivative (I) can be converted into a salt by adding an acid to the reaction solution or isolated one.
- the acid used is not particularly limited as long as it forms a salt.
- examples of such acids include hydrogen chloride, hydrogen bromide, hydrogen iodide, hydrochloric acid, hydrobromic acid, sulfuric acid, nitric acid, phosphoric acid, and boric acid; methanesulfonic acid, ethanesulfonic acid, benzene Sulfonic acids such as sulfonic acid, p-toluenesulfonic acid or camphorsulfonic acid; formic acid, acetic acid, propionic acid, oxalic acid, hydroxyacetic acid, citric acid, tartaric acid, succinic acid, maleic acid, benzoic acid, salicylic acid, fumaric acid, Or an organic carboxylic acid such as phthalic acid, preferably hydrogen chloride, hydrochloric acid, hydrobromic acid, sulfuric acid
- the amount of acid used is the same as that of 4-substituted-N 2 -methylbenzene-1,2-diamine derivative (I).
- an acid having an equivalent number or more necessary for the salt to be formed is used.
- tribasic acids such as boric acid or phosphoric acid
- dibasic acids such as sulfuric acid, oxalic acid, maleic acid, or tartaric acid
- hydrogen chloride In the case of monobasic acids such as hydrochloric acid, nitric acid, or methanesulfonic acid, 1 equivalent or more is used.
- the salt is usually formed in a solvent.
- the solvent is not particularly limited as long as it does not react under the reaction conditions for carrying out this step.
- Examples of such a solvent include water; alcohols such as methanol, ethanol, propanol, isopropyl alcohol, butanol, or isobutyl alcohol; diethyl ether, diisopropyl ether, dimethoxyethane, dibutyl ether, tetrahydrofuran, cyclopentyl methyl ether, or Ethers such as dioxane; esters such as methyl formate, ethyl formate, methyl acetate, ethyl acetate, propyl acetate, isopropyl acetate, or butyl acetate; nitriles such as acetonitrile, propionitrile, or benzonitrile; dimethylformamide, dimethyl Amides such as acetamide or N, N-dimethylimidazolidinone; hydrocarbons such as pentane, hexane, heptane, benzene, or toluene;
- the temperature at which the salt is formed is not particularly limited, but is usually ⁇ 20 ° C. to 200 ° C., preferably ⁇ 20 It is 0 degreeC thru
- the time for forming the salt depends on the 5-substituted-N-methyl-2-nitroaniline derivative (III ) Depending on the reaction conditions such as the solvent used, the concentration, the number of equivalents of the acid used, the reaction temperature, etc., usually 5 minutes to 5 days, preferably 10 minutes to 2 days, more preferably 30 minutes to 24. It's time.
- the condensing agent used is generally an amidation reaction.
- the condensing agent include dicyclohexylcarbodiimide (DCC), diisopropylcarbodiimide (DIPC), N-ethyl-N′-3-dimethylaminopropylcarbodiimide, and benzoic acid.
- Triazol-1-yl-tris (dimethylamino) phosphonium hexafluorophosphide salt BOP
- BOP Triazol-1-yl-tris (dimethylamino) phosphonium hexafluorophosphide salt
- methylphosphonic acid cyclic anhydride ethylphosphonic acid cyclic anhydride, propylphosphonic acid cyclic anhydride, butylphosphonic acid cyclic anhydride, polyphosphoric acid Ethyl ester (PPE), trimethylsilyl ester of polyphosphate
- PPE polyphosphoric acid Ethyl ester
- PPE polyphosphoric acid Ethyl ester
- trimethylsilyl ester of polyphosphate examples include stetel (PPSE), dimethyl phosphate cyanide, diethyl phosphate cyanide, dibutyl phosphate cyanide, diphenyl phosphate azide (DPPA), ditolyl phosphate
- the amount of the condensing agent used is not particularly limited as long as it is 1 equivalent or more with respect to ⁇ 4-[(2,4-dioxo-1,3-thiazolidin-5-yl) methyl] phenoxy ⁇ acetic acid, but usually 1 equivalent. To 3 equivalents, preferably 1 to 1.5 equivalents, more preferably 1 to 1.2 equivalents.
- the amount of acid chloride used is usually from 0.8 equivalents to 1.2 equivalents, preferably to ⁇ 4-[(2,4-dioxo-1,3-thiazolidin-5-yl) methyl] phenoxy ⁇ acetic acid. 0.9 equivalents to 1.1 equivalents, more preferably 0.95 equivalents to 1.05 equivalents.
- DBU 1,4-diazabicyclo [2.2.2] octane
- DBU 1,8-diazabicyclo [5.4.0] -7-undecene
- Organic amines preferably triethylamine, diisopropylethylamine, tripropylamine, Tributylamine or N-methylmorpholine is preferable, and triethylamine, tributylamine, or N-methylmorpholine is more preferable.
- Production of ⁇ 4-[(2,4-dioxo-1,3-thiazolidin-5-yl) methyl] phenoxy ⁇ acetic acid mixed anhydride is usually carried out in a solvent.
- the solvent is not particularly limited as long as it does not react under the production conditions of the mixed acid anhydride.
- Such solvents include ethers such as diethyl ether, diisopropyl ether, dimethoxyethane, dibutyl ether, tetrahydrofuran, cyclopentyl methyl ether, or dioxane; methyl formate, ethyl formate, methyl acetate, ethyl acetate, propyl acetate, isopropyl acetate, Or esters such as butyl acetate; nitriles such as acetonitrile, propionitrile, or benzonitrile; amides such as dimethylformamide, dimethylacetamide, or N, N-dimethylimidazolidinone; pentane, hexane, heptane, benzene, Or a hydrocarbon such as toluene, or a mixture thereof, preferably dibutyl ether, tetrahydrofuran, ethyl acetate, acetonitrile
- the reaction time for producing the above mixed acid anhydride is not particularly limited, but is usually 5 minutes to 24 hours, preferably 5 minutes to 12 hours, and more preferably 5 minutes to 6 hours. *
- the above mixed acid anhydride is usually used as it is after the production without isolation and purification.
- the amount of ⁇ 4-[(2,4-dioxo-1,3-thiazolidin-5-yl) methyl] phenoxy ⁇ acetic acid, its acid chloride or mixed acid anhydride used in this step is usually 4- 0.8 equivalents to 1.2 equivalents, preferably 0.9 equivalents to 1.1 equivalents, more preferably, relative to the substituted —N 2 -methylbenzene-1,2-diamine derivative (I) or a salt thereof. Is 0.95 equivalents to 1.05 equivalents.
- a base is generally used for the amidation in this step.
- the base used include trimethylamine, triethylamine, diisopropylethylamine, tripropylamine, triisopropylamine, tributylamine, N-methylmorpholine, pyridine, 4- (N, N-dimethylamino) pyridine, N, N-dimethylaniline, N , N-diethylaniline, 1,5-diazabicyclo [4.3.0] nano-5-ene, 1,4-diazabicyclo [2.2.2] octane (DABCO), or 1,8-diazabicyclo [5.
- N-hydroxysuccinimide, 1-hydroxybenzotriazole, 3-hydroxy-4-oxo-3,4-dihydro-1,2,3-benzotriazine or the like is added to obtain a higher yield. May improve and shorten the reaction time.
- N-hydroxysuccinimide, 1-hydroxybenzotriazole, 3-hydroxy-4-oxo-3,4-dihydro-1,2,3-benzotriazine or the like is added, the amount used is ⁇ 4-[(2 , 4-Dioxo-1,3-thiazolidin-5-yl) methyl] phenoxy ⁇ acetic acid, its acid chloride or mixed anhydride, usually 0.001 equivalent to 1 equivalent, preferably 0.01 equivalent to 1 equivalent is used.
- the reaction temperature in this step is usually ⁇ 50 ° C. to 20 ° C., preferably ⁇ 30 ° C. to 20 ° C., more preferably ⁇ 20 ° C. to 10 ° C. *
- the reaction time in this step is not particularly limited, but is usually 5 minutes to 24 hours, preferably 5 minutes to 12 hours, and more preferably 5 minutes to 6 hours.
- novel amide compound (II) produced in this step may be used as it is in the next step without being isolated, or may be isolated by ordinary post-treatment.
- a novel amide compound (II) is subjected to dehydration condensation within a molecule in a solvent in the presence of an acid, and a protecting group of a nitrogen atom is deprotected as necessary, whereby a 6-substituted-1-
- This is a process for producing methyl-1H-benzimidazole derivative (IV) or a salt thereof, or a hydrate thereof.
- the solvent used in this step is not particularly limited as long as it does not react with the amide compound (II) and dissolves to some extent.
- solvents include, for example, water; alcohols such as methanol, ethanol, propanol, isopropyl alcohol, butanol, or isobutyl alcohol; diethyl ether, diisopropyl ether, dimethoxyethane, dibutyl ether, tetrahydrofuran, cyclopentyl methyl ether, or dioxane.
- Ethers such as acetonitrile; nitriles such as acetonitrile, propionitrile, or benzonitrile; amides such as dimethylformamide, dimethylacetamide, or N, N-dimethylimidazolidinone; pentane, hexane, heptane, benzene, or toluene Hydrocarbons such as dichloromethane, chloroform, or halogenated hydrocarbons such as 1,2-dichloroethane, or mixtures thereof, preferably , Water, nitriles, alcohols, ethers and mixtures thereof, more preferably water, acetonitrile, methanol, ethanol, tetrahydrofuran, dioxane, or mixtures thereof, particularly preferably water-acetonitrile mixtures. Solvent or water-tetrahydrofuran mixed solvent.
- the acid used in this step may be either Bronsted acid or Lewis acid, but usually Bronsted acid is used.
- the Bronsted acid usually used in this step is not particularly limited, but examples thereof include inorganic acids such as hydrogen chloride, hydrogen bromide, hydrochloric acid, bromic acid, sulfuric acid, nitric acid, phosphoric acid and boric acid, formic acid, acetic acid and propionic acid.
- the acid of the salt to be produced can be used as it is to obtain a corresponding salt.
- the reaction temperature in this step varies depending on the properties of the amide compound (II), acid and solvent, but is usually 0 ° C. to 150 ° C., preferably 220 ° C. to 100 ° C., more preferably 30 ° C. to 80 ° C. ° C. *
- the reaction time in this step varies depending on the properties of the amide compound (II), the acid and the solvent. 30 minutes to 20 hours, preferably 1 hour to 10 hours.
- some of the protecting groups of nitrogen atoms substituted with R 1 and / or R 2 may be deprotected during the above reaction, but in the case of a group that is not deprotected, a deprotecting reaction is performed as necessary. I do.
- a deprotection reaction a deprotection reaction generally used in organic synthesis (for example, a reaction described in TWGreene et al., Protective Groups in Organic Synthesis, John Willey & Sons, Inc.) can be employed, and is suitable.
- the deprotection reaction under neutral or acidic conditions is employed.
- the compound (IV) or a salt thereof, or a hydrate thereof crystallizes as a crystal, it can be isolated by a filtration operation.
- compound (IV) or a salt thereof, or a hydrate thereof does not become a crystal, it can be isolated by an isolation operation such as an extraction operation after a normal post-treatment.
- the obtained compound (IV) or a salt thereof, or a hydrate thereof may be further subjected to ordinary purification operations such as recrystallization and column chromatography.
- the recrystallization is performed by (1) a method in which the obtained compound (IV) or a salt thereof, or a hydrate thereof is dissolved by heating and then cooling, and (2) a method in which the solvent is distilled off and concentrated after dissolution, (3) It is achieved by a method usually used in the field of synthetic organic chemistry, such as a method of precipitating crystals by dissolving in a good solvent and adding a poor solvent.
- the method for purifying the obtained compound (IV) or a salt thereof, or a hydrate thereof can be performed according to the method described in JP-T 2010-517932 (International Publication No. 2008/099944 pamphlet). . It is known that compound (IV) and salts thereof (particularly preferably hydrochloride) and hydrates thereof have an excellent ability to activate peroxisome proliferator activated receptor (PPAR) ⁇ . It is as disclosed in the gazette (patent document 2), the international publication 2007/091622 pamphlet, etc.
- the 6-substituted-1-methyl-1H-benzimidazole derivative represented by the general formula (IV) of the present invention, or a salt thereof, or a hydrate thereof is useful as a pharmaceutical, particularly as a PPAR ⁇ activator. Moreover, it is useful as a therapeutic agent or preventive agent (anticancer pharmaceutical composition) for various cancer types as described above.
- Example 1 4- (4-amino-3,5-dimethylphenoxy) -N 2 -methylbenzenediamine (compound number: (I) -1, first step) To a solution of 2,6-dimethyl-4- [3- (methylamino) -4-nitrophenoxy] aniline (3.5 g) in methanol (35 mL) was added 7.5% palladium on carbon catalyst (0.74 g). The system was degassed under reduced pressure and then purged with nitrogen. The mixture was further degassed under reduced pressure, replaced with hydrogen, and stirred under the same atmosphere (1 atm) for 4.5 hours. The reaction mixture was filtered and concentrated to obtain the target compound (3.18 g, yield 100%).
- Example 3 5- (4- ⁇ [6- (4-Amino-3,5-dimethylphenoxy) -1-methyl-1H-benzimidazol-2-yl] methoxy ⁇ benzyl) -1,3-thiazolidine-2,4- Dione dihydrochloride monohydrate (third step) N-[(4-amino-3,5-dimethylphenoxy) -2- (methylamino) phenyl] -2- ⁇ 4-[(2,4-dioxo-1,3-thiazolidine-) obtained in Example 2 Concentrated hydrochloric acid (1 mL) was added to a solution of 5-yl) methyl] phenoxy ⁇ acetamide (1.27 g) in methanol (25 mL) at room temperature and refluxed for about 1 hour.
- Example 4 4- (4-Amino-3,5-dimethylphenoxy) -N 2 -methylbenzenediamine dihydrochloride (Compound No: (I) -1 dihydrochloride, first step) To a solution of 2,6-dimethyl-4- [3- (methylamino) -4-nitrophenoxy] aniline in water-wet crystals (13.88 kg, corresponding to a dry weight of about 12 kg) in ethyl acetate (126 L), 2,6 -Di-t-butyl-4-methylphenol (0.13 kg) 5% palladium on carbon catalyst (0.64 kg) was added, vacuum degassed, purged with nitrogen, heated to about 50 ° C, vacuum degassed, hydrogen Replaced.
- the mixture was stirred at the same temperature for 3 hours under a hydrogen atmosphere (0.35 MPa), cooled to 20 ° C., and the reaction mixture was filtered.
- the reaction vessel and the filtrate were washed with a solution of 2,6-di-t-butyl-4-methylphenol (0.09 kg) in 2-propanol (85 L).
- the filtrate and the washing solution were combined, 38% hydrochloric acid (21.25 kg) was added dropwise thereto at 20 ° C., and the mixture was stirred at 5 ° C. for 1 hour and allowed to stand for 12 hours.
- the obtained crystals were collected by filtration, washed with ethyl acetate (68 L), and dried under reduced pressure at 40 ° C.
- Example 9 (4- ⁇ 4-[( ⁇ 4-[(2,4-Dioxo-1,3-thiazolidin-5-yl) methyl] phenoxy ⁇ acetyl) amino] -3- (methylamino) phenoxy ⁇ -2,6 -Dimethylphenyl) carbamate t-butyl (compound number: (II) -10, second step) ⁇ 4-[(2,4-Dioxo-1,3-thiazolidin-5-yl) methyl] phenoxy ⁇ acetic acid (747 mg) in ethyl acetate (6 mL) at 0 ° C.
- Example 11 The obtained crystals were collected by filtration, washed with methanol (10 mL), and then dried under reduced pressure to obtain the target compound (1090 mg, yield 69% (based on phenoxyacetic acid).
- the NMR spectrum of this compound was obtained in Example 3.
- Example 11 5- (4- ⁇ [6- (4-Amino-3,5-dimethylphenoxy) -1-methyl-1H-benzimidazol-2-yl] methoxy ⁇ benzyl) -1,3-thiazolidine-2,4- Dione dihydrochloride monohydrate
- 5- (4- ⁇ [6- (4-amino-3,5-dimethylphenoxy) -1-methyl-1H-benzimidazole-2] obtained according to the method of Example 7 -Il] methoxy ⁇ benzyl) -1,3-thiazolidine-2,4-dione dihydrochloride monohydrate (22.50 kg) in water (450 L) was stirred at 80 ° C.
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Diabetes (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Emergency Medicine (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Endocrinology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
- Thiazole And Isothizaole Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Abstract
Description
しかし4-置換-N2-メチルベンゼン-1、2―ジアミン類のアミノ基を保護することなく高品質の6-置換-1-メチル-1H-ベンズイミダゾール誘導体が高収率で製造できれば、保護基導入と脱保護の二工程が短縮され、また保護基導入や脱保護のための反応剤を削減することとなり、より工業的に有利な製造法を提供することが可能となる。4-置換-N2-メチルベンゼン-1、2―ジアミン類のアミノ基の保護基を使用しない6-置換-1-メチル-1H-ベンズイミダゾール誘導体の製造法としては、4-置換-N2-メチルベンゼン-1、2―ジアミン類とカルボン酸エステルとの反応による方法(特許文献1)、あるいは5-置換-N-メチル-2-ニトロアニリン類と酸塩化物とを反応させ対応するアミド体を得、さらにニトロ基還元する方法(特許文献7)が知られている。しかしいずれの方法も目的とする6-置換-1-メチル-1H-ベンズイミダゾール誘導体の収率が低く、工業的製法としては十分なものでは無かった。
(2)上記(1)において、酸が塩酸であり、R1が水素原子を表し、R2が水素原子又t-ブトキシカルボニル基を表す製造方法、(3)下記一般式(II):
(4)上記(3)において、R1が水素原子を表し、R2が水素原子又t-ブトキシカルボニル基を表す化合物、
(5)下記一般式(I):
(6)上記(5)において、R1が水素原子を表し、R2が水素原子又t-ブトキシカルボニル基を表す製造方法、
(7)下記一般式(I):
(8)上記(7)において、R1が水素原子を表し、R2が水素原子又t-ブトキシカルボニル基を表す製造方法、
(9)下記一般式(I):
(10)上記9において、R1が水素原子を表し、R2が水素原子又t-ブトキシカルボニル基を表す4-置換-N2-メチルベンゼン-1、2―ジアミン誘導体又はその塩、
(11)下記一般式(III):
(12)上記(11)において、R1が水素原子を表し、R2が水素原子又t-ブトキシカルボニル基を表す製造方法、及び
(13)下記一般式(III):
ついで、上記式(I)で表される4-置換-N2-メチルベンゼン-1、2―ジアミン誘導体と、{4-[(2,4-ジオキソ-1,3-チアゾリジン-5-イル)メチル]フェノキシ}酢酸とを、縮合剤の存在下で反応させるか、若しくは、上記式(I)で表される4-置換-N2-メチルベンゼン-1、2―ジアミン誘導体と、{4-[(2,4-ジオキソ-1,3-チアゾリジン-5-イル)メチル]フェノキシ}酢酸の酸塩化物または混合酸無水物とを反応させて、
下記一般式(II):
ついで、上記式(II)を有する化合物を、酸の存在下、分子内で脱水縮合させ、必要に応じて窒素原子の保護基を脱保護することを特徴とする下記一般式(I):
である。 本発明においてC1-C4アルキル基とは、炭素数1乃至4個の直鎖又は分岐鎖のアルキル基であり、例えば、メチル基、エチル基、プロピル基、ブチル基、イソプロピル基、イソブチル基、s-ブチル基、またはt-ブチル基である。好ましくは、メチル基、エチル基、プロピル基、ブチル基、又はイソブチル基である。より好ましくは、メチル基である。
アラルキル基としては、例えば、4-メチルベンジル、2,4,6-トリメチルベンジル、3,4,5-トリメチルベンジル、4-メトキシベンジル、2-ニトロベンジル、4-ニトロベンジル、4-クロロベンジル、4-ブロモベンジル、4-シアノベンジルのような、1乃至3個の低級アルキル、低級アルコキシ、ニトロ、ハロゲン又はシアノ基でアリ-ル環が置換されたアラルキル基である。
塩酸塩である。
Me:メチル
Et:エチル
Pr:プロピル
iPr:イソプロピル
Bu:n-ブチル
iBu:イソブチル
sBu:s-ブチル
tBu:t-ブチル
Boc:t-ブトキシカルボニル
化合物番号 化合物番号 R 1 R 2
(I)-1 (II)-1 H H
(I)-2 (II)-2 Me H
(I)-3 (II)-3 Et H
(I)-4 (II)-4 Pr H
(I)-5 (II)-5 iPr H
(I)-6 (II)-6 Bu H
(I)-7 (II)-7 iBu H
(I)-8 (II)-8 sBu H
(I)-9 (II)-9 tBu H
(I)-10 (II)-10 Boc H
(I)-11 (II)-11 H Boc
(I)-12 (II)-12 Me Boc
(I)-13 (II)-13 Et Boc
(I)-14 (II)-14 Pr Boc
(I)-15 (II)-15 iPr Boc
(I)-16 (II)-16 Bu Boc
(I)-17 (II)-17 iBu Boc
(I)-18 (II)-18 sBu Boc
(I)-19 (II)-19 tBu Boc
本発明の一般式(I)を有する化合物において好適な化合物としては、例示化合物番号:(I)-1、(I)-2、(I)-3、(I)-4、(I)-6、(I)-7、(I)-11、および(I)-12であり、より好適には(I)-1、(I)-2、および(I)-11であり、さらに好適には(I)-1および(I)-11であり、よりさらに好適には(I)-1である。
4-置換-N2-メチルベンゼン-1、2―ジアミン誘導体(I)またはそれらの塩と4-[(2,4-ジオキソチアゾリジン-5-イル)メチル]フェノキシ酢酸とを、縮合剤の存在下反応させるか、もしくは、4-置換-N2-メチルベンゼン-1、2―ジアミン誘導体(I)またはそれらの塩と4-[(2,4-ジオキソチアゾリジン-5-イル)メチル]フェノキシ酢酸の酸塩化物または混合酸無水物と反応させて、新規なアミド化合物(II)を製造する第二工程、および
新規なアミド化合物(II)を酸の存在下脱水縮合させて6-置換-1-メチル-1H-ベンズイミダゾール誘導体(IV)またはそれらの塩を得る第三工程からなる。以下に各工程について詳しく説明する。
本工程は、溶媒中、触媒の存在下で5-置換-N-メチル-2-ニトロアニリン誘導体(III)のニトロ基を接触水素添加によって還元して、4-置換-N2-メチルベンゼン-1、2―ジアミン誘導体(I)を製造する工程である。
本工程は一般にアミド化と呼ばれ、溶媒中、塩基の存在下、(i)4-置換-N2-メチルベンゼン-1、2―ジアミン誘導体(I)を、縮合剤を用いて{4-[(2,4-ジオキソ-1,3-チアゾリジン-5-イル)メチル]フェノキシ}酢酸と反応させるか、もしくは、(ii){4-[(2,4-ジオキソ-1,3-チアゾリジン-5-イル)メチル]フェノキシ}酢酸を酸塩化物あるいは混合酸無水物とし、この酸塩化物あるいは混合酸無水物と、4-置換-N2-メチルベンゼン-1、2―ジアミン誘導体(I)またはそれらの塩とを、反応させることによって、新規なアミド化合物(II)を製造する工程である。尚、本工程の出発化合物である4-置換-N2-メチルベンゼン-1、2―ジアミン誘導体(I)は塩として用いてもよい。塩としては、前述の(第一工程)に記載の、4-置換-N2-メチルベンゼン-1、2―ジアミン誘導体(I)の塩を用いることができる。
本工程は、新規なアミド化合物(II)を、溶媒中、酸の存在下、分子内で脱水縮合させ、必要に応じて窒素原子の保護基を脱保護させることにより、6-置換-1-メチル-1H-ベンズイミダゾール誘導体(IV)若しくはその塩、またはこれらの水和物製造する工程である。
本工程でアミド化合物(II)が溶媒に溶解する場合、酸を添加する前に濾過操作を行う事で化合物(II)に混入している無機性あるいは有機性の難溶性不純物を取り除くことができる。
30分間乃至20時間であり、好適には1時間乃至10時間である。
得られた化合物(IV)若しくはその塩、またはこれらの水和物は、さらに再結晶、カラムクロマトグラフィー等の通常の精製操作を行ってもよい。
化合物(IV)及びその塩(特に好ましくは塩酸塩)、及びこれらの水和物が、優れたペルオキシソーム増殖因子活性化受容体(PPAR)γ活性化能を示すことは、特開平11-193276号公報(特許文献2)、国際公開第2007/091622号パンフレット等に開示されるとおりである。
4-(4-アミノ-3,5-ジメチルフェノキシ)-N2-メチルベンゼンジアミン(化合物番号:(I)-1、第一工程)
2,6-ジメチル-4-[3-(メチルアミノ)-4-ニトロフェノキシ]アニリン(3.5g)のメタノール(35mL)溶液に、7.5%パラジウム炭素触媒(0.74g)を添加し、系内を減圧脱気後、窒素置換した。さらに減圧脱気し、水素置換し同雰囲気下(1気圧)、4.5時間攪拌した。反応混合物をろ過後、濃縮し、目的化合物(3.18g、収率100%)を得た。
NMR(400MHz,DMSO-d6)δppm:2.04(s,6H),2.63(d,J=5.2Hz,3H),4.17(brs,1H),4.22(brs,2H),4.71(q,J=5.2Hz,1H),5.93(dd,J=2.7Hz,J=8.2Hz,1H),6.03(d,J=2.7Hz,1H),6.43(d,J=8.2Hz,1H),6.45(s,2H)。
N-[(4-アミノ-3,5-ジメチルフェノキシ)-2-(メチルアミノ)フェニル]-2-{4-[(2,4-ジオキソ-1,3-チアゾリジン-5-イル)メチル]フェノキシ}アセトアミド(化合物番号:(II)-1、第二工程)
実施例1で得た4-(4-アミノ-3,5-ジメチルフェノキシ)-N2-メチルベンゼンジアミン(3.18g)のジクロロメタン(31mL)溶液に{4-[(2,4-ジオキソ-1,3-チアゾリジン-5-イル)メチル]フェノキシ}酢酸(3.76g)を加え、0℃に冷却後、トリエチルアミン(3.73mL)、ついでプロピルホスホン酸環状無水物の50%酢酸エチル溶液(8.69mL)を滴下し、0℃乃至10℃で40分間攪拌した。ここへ5%重曹水(31mL)を加えよく攪拌した後、分液した。有機層を水(15mL)で洗浄後、濃縮し、目的化合物(5.72g、収率97%(フェノキシ酢酸基準))を得た。
NMR(400MHz,DMSO-d6)δppm:2.07(s,6H),2.61(d,J=4.6Hz,3H),3.08(dd,J=9.2Hz,J=14.2Hz,1H),3.31(dd,J=10.2Hz,J=14.2Hz,1H),4.63(s,2H),4.89(dd,J=9.2Hz,J=10.2Hz,1H),5.17(brq,J=4.6Hz,1H),5.95(dd,J=2.6Hz,J=8.3Hz,1H),6.13(d,J=2.6Hz,1H),6.56(s,2H),6.89(d,J=8.3Hz,1H),6.96(d,J=8.6Hz,2H),7.18(d,J=8.6Hz,2H),9.11(s,1H)。
5-(4-{[6-(4-アミノ-3,5-ジメチルフェノキシ)-1-メチル-1H-ベンツイミダゾール-2-イル]メトキシ}ベンジル)-1,3-チアゾリジン-2,4-ジオン 2塩酸 1水和物(第三工程)
実施例2で得たN-[(4-アミノ-3,5-ジメチルフェノキシ)-2-(メチルアミノ)フェニル]-2-{4-[(2,4-ジオキソ-1,3-チアゾリジン-5-イル)メチル]フェノキシ}アセトアミド(1.27g)のメタノール(25mL)溶液に、室温で濃塩酸(1mL)を加え、約1時間還流した。室温まで冷却後、濃縮した。得られた残渣にメタノール(5mL)、酢酸エチル(20mL)を加え、約1時間攪拌した。得られた粉末をろ別、メタノール-酢酸エチル(1:4)混合溶媒で洗浄、減圧乾燥し、目的化合物(1.24g、収率86%)を得た。
NMR(400MHz,DMSO-d6)δppm:2.35(s,6H),3.10(dd,J=8.9Hz,J=14.1Hz,1H),3.34(dd,J=4.5Hz,J=14.1Hz,1H),3.94(s,3H),4.91(dd,J=4.5Hz,J=8.9Hz,1H),5.64(s,2H),6.81(s、2H),7.14(d,J=8.3Hz,2H),7.21(dd,J=2.1Hz,J=8.7Hz,1H),7.25(d,J=8.3Hz,2H),7.64(d,J=2.1Hz,1H),7.81(d,J=8.7Hz,1H),12.06(brs,1H)。
4-(4-アミノ-3,5-ジメチルフェノキシ)-N2-メチルベンゼンジアミン 2塩酸(化合物番号:(I)-1の2塩酸塩、第一工程)
2,6-ジメチル-4-[3-(メチルアミノ)-4-ニトロフェノキシ]アニリンの水湿品結晶(13.88kg、乾燥重量約12kg相当)の酢酸エチル(126L)溶液に、2,6-ジ-t-ブチル-4-メチルフェノール(0.13kg)5%パラジウム炭素触媒(0.64kg)を添加し、減圧脱気、窒素置換後、約50℃に加熱し、減圧脱気、水素置換した。水素雰囲気下(0.35MPa)、同温度で3時間攪拌し、20℃に冷却後、反応混合物をろ過した。反応容器内およびろ過物を2,6-ジ-t-ブチル-4-メチルフェノール(0.09kg)の2-プロパノール(85L)溶液で洗浄した。ろ液と洗浄液を合わせ、ここへ20℃で、38%塩酸(21.25kg)を滴下し、5℃で1時間攪拌後、12時間静置した。得られた結晶をろ別し、酢酸エチル(68L)で洗浄後、40℃で減圧乾燥し、目的化合物(12.96kg、94%)を得た。
NMR(400MHz,DMSO-d6)δppm:2.28(s,6H),2.66(s,3H),6.20(dd,J=2.3Hz,J=8.6Hz,1H),6.36(d,J=2.3Hz,1H),6.74(s,2H),7.17(d,J=8.6Hz,1H),9.64(brs,5H)。
5-(4-{[6-(4-アミノ-3,5-ジメチルフェノキシ)-1-メチル-1H-ベンツイミダゾール-2-イル]メトキシ}ベンジル)-1,3-チアゾリジン-2,4-ジオン 2塩酸 1水和物(第二、第三工程)
{4-[(2,4-ジオキソ-1,3-チアゾリジン-5-イル)メチル]フェノキシ}酢酸(11.04kg)のテトラヒドロフラン(130L)懸濁液に、トリブチルアミン(7.27kg)を添加し溶液とした。-5℃に冷却し、塩化ピバロイル(4.73kg)を滴下後、-10℃で30分間攪拌し、{4-[(2,4-ジオキソ-1,3-チアゾリジン-5-イル)メチル]フェノキシ}酢酸とピバリン酸の混合酸無水物を得た。この混合酸無水物を、-10℃に冷却した、実施例4で得た4-(4-アミノ-3,5-ジメチルフェノキシ)-N2-メチルベンゼンジアミン 2塩酸(12.96kg)とトリブチルアミン(24.00kg)のテトラヒドロフラン(130L)の溶液に77分間かけて滴下し、さらに1時間攪拌し、N-[(4-アミノ-3,5-ジメチルフェノキシ)-2-(メチルアミノ)フェニル]-2-{4-[(2,4-ジオキソ-1,3-チアゾリジン-5-イル)メチル]フェノキシ}アセトアミドのテトラヒドロフラン混合液を得た。得られた混合液を0℃まで昇温し、水(130L)、38%塩酸(11.01kg)を添加後、60℃で30分間攪拌した。得られた反応液を5℃に冷却し12時間攪拌後、20℃で25%水酸化ナトリウム水溶液(19.44kg)、塩化ナトリウム(24.92kg)の水(130L)溶液を滴下し、15分間攪拌後、1.5時間静置し、水層(下層)を排出した。得られた5-(4-{[6-(4-アミノ-3,5-ジメチルフェノキシ)-1-メチル-1H-ベンツイミダゾール-2-イル]メトキシ}ベンジル-2,4-ジオキソ-1,3-チアゾリジンの溶液(上層)に活性炭(3.89kg)のテトラヒドロフラン(65L)懸濁液を添加し、20℃で40分間攪拌した。活性炭をろ別し、反応容器と活性炭をテトラヒドロフラン(91L)で洗浄した。ろ液、洗浄液を合わせ、-10℃で12時間攪拌した。この溶液を容積が約260Lとなるまで、約20℃で減圧濃縮した。この濃縮液に30℃で、38%塩酸(18.79kg)のテトラヒドロフラン(65L)溶液を1.5時間かけて滴下し、5℃に冷却した。さらに1時間攪拌後、得られた結晶をろ別し、水(4L)とテトラヒドロフラン(35L)、ついで水(65L)で洗浄し、目的化合物の湿品結晶(23.80kg)を得た。これを一部サンプリングし、40℃で減圧乾燥したもののNMRスペクトルは、実施例3で得られたものと一致した。
4-(4-アミノ-3,5-ジメチルフェノキシ)-N2-メチルベンゼンジアミン 2塩酸(化合物番号:(I)-1の2塩酸塩、第一工程)
2,6-ジメチル-4-[3-(メチルアミノ)-4-ニトロフェノキシ]アニリン(35.0g)のテトラヒドロフラン(350mL)溶液に、水(35mL)、50%湿品-5%パラジウム炭素触媒(1.86g)を添加した。系内を減圧脱気後、窒素置換した。約60℃に加熱し、さらに減圧脱気し、水素置換し同雰囲気下(0.1MPa)、2時間攪拌した。減圧脱気し窒素置換後5℃に冷却し、反応混合物をろ過し、容器内およびろ過物をテトラヒドロフラン(70mL)で洗浄した。ろ液と洗浄液を合わせ、0~5℃まで冷却し、ここへテトラヒドロフラン(105mL)で希釈した38%塩酸(29.2g)を20分間かけて滴下し、さらに同温度で1時間攪拌した。得られた結晶をろ別し、テトラヒドロフラン(175mL)で洗浄後、40℃で減圧乾燥し目的化合物(38.3g、収率95%)を得た。得られた化合物のNMRスペクトルは実施例4で得られたものと一致した。
5-(4-{[6-(4-アミノ-3,5-ジメチルフェノキシ)-1-メチル-1H-ベンツイミダゾール-2-イル]メトキシ}ベンジル)-1,3-チアゾリジン-2,4-ジオン 2塩酸 1水和物(第二、第三工程)
{4-[(2,4-ジオキソ-1,3-チアゾリジン-5-イル)メチル]フェノキシ}酢酸(17.03g)のテトラヒドロフラン(50mL)懸濁液に、-20℃で塩化ピバロイル(7.30g)を滴下後、-20℃乃至-10℃でトリブチルアミン(11.22g)を滴下した。得られた反応溶液を1時間攪拌し、{4-[(2,4-ジオキソ-1,3-チアゾリジン-5-イル)メチル]フェノキシ}酢酸とピバリン酸の混合酸無水物を得た。この混合酸無水物の溶液を、-20℃に冷却した、実施例6で得た4-(4-アミノ-3,5-ジメチルフェノキシ)-N2-メチルベンゼンジアミン 2塩酸(20.00g)とトリブチルアミン(37.04g)のテトラヒドロフラン(90mL)の溶液に、-20℃乃至-10℃で1時間かけて滴下し、さらに混合酸無水物の反応容器をテトラヒドロフランで(30mL)で洗い込んだ。反応液を同温度で1時間攪拌し、N-[(4-アミノ-3,5-ジメチルフェノキシ)-2-(メチルアミノ)フェニル]-2-{4-[(2,4-ジオキソ-1,3-チアゾリジン-5-イル)メチル]フェノキシ}アセトアミドのテトラヒドロフラン混合液を得た。ここへ、水(64mL)、38%塩酸(12.20g)を添加後、3時間還流し、5-(4-{[6-(4-アミノ-3,5-ジメチルフェノキシ)-1-メチル-1H-ベンツイミダゾール-2-イル]メトキシ}ベンジル-2,4-ジオキソ-1,3-チアゾリジンの塩酸塩混合液を得た。得られた反応液に60℃で、トリブチルアミン(8.98g)とテトラヒドロフラン(240mL)を滴下し、5-(4-{[6-(4-アミノ-3,5-ジメチルフェノキシ)-1-メチル-1H-ベンツイミダゾール-2-イル]メトキシ}ベンジル-2,4-ジオキソ-1,3-チアゾリジンの水-テトラヒドロフラン溶液とし、ここへ減圧脱気した活性炭(3.4g)のテトラヒドロフラン(30mL)懸濁液を加えた。この混合物を60℃で1時間攪拌した後、活性炭をろ別し、反応容器内と活性炭をテトラヒドロフラン(70mL)で洗浄した。ろ液と洗浄液を合わせ50℃とした後、水(86mL)ついで38%塩酸(29.05g)を滴下し、同温度で12時間攪拌した。得られた結晶をろ別し、テトラヒドロフラン(120mL)で洗浄後、3.3kPa,50℃で乾燥し、目的化合物(32.93g、92%(フェノキシ酢酸基準))を得た。このもののNMRスペクトルは、実施例3で得られたものと一致した。
{4-[4-アミノ-3-(メチルアミノ)フェノキシ]-2,6-ジメチルフェニル}カルバミン酸t-ブチル(化合物番号:(I)-10、第一工程)
{2,6-ジメチル-4-[3-(メチルアミノ)-4-ニトロフェノキシ]フェニルカルバミン酸t-ブチル(2.0g)のメタノール(23mL)-テトラヒドロフラン(5mL)の混合溶液に40℃で50%湿品-10%パラジウム炭素触媒(200mg)を加え、脱気後、水素置換した。水素雰囲気下(3気圧)、40℃で3時間攪拌した。室温まで冷却後、パラジウム炭素をろ別し、反応容器内とパラジウム炭素をメタノール(40mL)で洗浄した。ろ液と洗浄液を合わせ減圧濃縮し、目的化合物(1.94g、収率100%)を得た。
HPLC(カラム:L-column ODS 4.6 × 250mm,移動層:アセトニトリル-0.02M酢酸アンモニウム水溶液=6対4,流速:1.0mL/min,カラム温度:40℃,検出波長:220nm)保持時間(分):7.34.
(実施例9)
(4-{4-[({4-[(2,4-ジオキソ-1,3-チアゾリジン-5-イル)メチル]フェノキシ}アセチル)アミノ]-3-(メチルアミノ)フェノキシ}-2,6-ジメチルフェニル)カルバミン酸t-ブチル(化合物番号:(II)-10、第二工程)
{4-[(2,4-ジオキソ-1,3-チアゾリジン-5-イル)メチル]フェノキシ}酢酸(747mg)の酢酸エチル(6mL)溶液に0℃で塩化ピバロイル(320mg)、ついでトリブチルアミン(493mg)を滴下し、30分間攪拌した。得られた混合酸無水物の溶液を、実施例8で得られた{4-[4-アミノ-3-(メチルアミノ)フェノキシ]-2,6-ジメチルフェニル}カルバミン酸t-ブチル(970mg)とトリエチルアミン(717mg)の酢酸エチル(8mL)溶液に0℃で滴下し、同温度で1時間攪拌した。反応混合液に酢酸エチル(10mL)、水(20mL)を注加し、有機層を分液後、10%塩酸(20mL)で2回、5%重曹水(20mL)で2回、水(20mL)で1回洗浄し、無水硫酸マグネシウム乾燥した。無水硫酸マグネシウムをろ別後、有機層を濃縮し、目的化合物を得た。
HPLC(カラム:L-column ODS 4.6 × 250mm,移動層:アセトニトリル-0.02M酢酸アンモニウム水溶液=1対1,流速:1.0mL/min,カラム温度:40℃,検出波長:220nm)保持時間(分):12.01.
(実施例10)
5-(4-{[6-(4-アミノ-3,5-ジメチルフェノキシ)-1-メチル-1H-ベンツイミダゾール-2-イル]メトキシ}ベンジル)-1,3-チアゾリジン-2,4-ジオン 2塩酸 1水和物(第三工程)
実施例9で得た、(4-{4-({4-[(2,4-ジオキソ-1,3-チアゾリジン-5-イル)メチル]フェノキシ}アセチル)アミノ]-3-(メチルアミノ)フェノキシ-2,6-ジメチルフェニル}カルバミン酸t-ブチルのメタノール(20mL)溶液に、室温で38%塩酸(1238mg)を加え1時間攪拌し、さらに1時間還流後、0℃まで冷却した。得られた結晶をろ別し、メタノール(10mL)で洗浄後、減圧乾燥し、目的化合物(1090mg、収率69%(フェノキシ酢酸基準))を得た。このもののNMRスペクトルは、実施例3で得られたものと一致した。
(実施例11)
5-(4-{[6-(4-アミノ-3,5-ジメチルフェノキシ)-1-メチル-1H-ベンツイミダゾール-2-イル]メトキシ}ベンジル)-1,3-チアゾリジン-2,4-ジオン 2塩酸 1水和物
実施例7の方法に準じて得られた5-(4-{[6-(4-アミノ-3,5-ジメチルフェノキシ)-1-メチル-1H-ベンツイミダゾール-2-イル]メトキシ}ベンジル)-1,3-チアゾリジン-2,4-ジオン 2塩酸 1水和物(22.50kg)の水(450L)懸濁液を80℃で30分間攪拌後、38%塩酸(14.55kg)を水(113L)で希釈した塩酸を1.5時間かけて加えた。1時間攪拌後、40℃に冷却し、18時間攪拌した。得られた結晶をろ別し、38%塩酸(1.75kg)を水(68L)で希釈した塩酸で洗浄後、4.3kPa,50℃で乾燥し、目的化合物(21.49kg、収率96%)を得た。このものの粉末X線回折(CuKα、λ=1.54オングストローム)の回折パターンを図1に、図1に示す回折パターン図において最大ピーク強度を100とした場合の相対強度10以上のピークを表2に示す。図1中のピーク番号は表2中のピーク番号に対応する。
(表2)
5-(4-{[6-(4-アミノ-3,5-ジメチルフェノキシ)-1-メチル-1H-ベンツイミダゾール-2-イル]メトキシ}ベンジル)-1,3-チアゾリジン-2,4-ジオン 2塩酸 1水和物の純度測定
実施例7で得た表記化合物を以下のHPLC条件で分析し、純度を測定した結果を表2に示す。
カラム:XTerra RP18 (Waters社製4.6mm x 150mm)
カラム温度:約40℃の一定温度
移動層:0.01M酢酸アンモニウム緩衝液(pH4.5):アセトニトリル
=65:35
流量:約1mL/分(目的化合物の保持時間が約25分となるよう設定)
検出波長:230nm
試料溶液調整法:分析対象化合物約0.05gを50mLのメスフラスコに量り取り、水-アセトニトリル(3:2)混合液を加え溶解後、さらに水-アセトニトリル(3:2)混合液を50mLとなるまで加える。
測定時間:試料溶液注入後70分間。
(表3)
Claims (13)
- 請求項1において、酸が塩酸であり、R1が水素原子を表し、R2が水素原子又t-ブトキシカルボニル基を表す製造方法。
- 請求項3において、R1が水素原子を表し、R2が水素原子又t-ブトキシカルボニル基を表す化合物。
- 請求項5において、R1が水素原子を表し、R2が水素原子又t-ブトキシカルボニル基を表す製造方法。
- 請求項7において、R1が水素原子を表し、R2が水素原子又t-ブトキシカルボニル基を表す製造方法。
- 請求項9において、R1が水素原子を表し、R2が水素原子又t-ブトキシカルボニル基を表す4-置換-N2-メチルベンゼン-1、2―ジアミン誘導体又はその塩。
- 請求項11において、R1が水素原子を表し、R2が水素原子又t-ブトキシカルボニル基を表す製造方法。
- 下記一般式(III):
[式中、R1は水素原子、C1-C4アルキル基、または窒素原子の保護基を、R2は水素原子または窒素原子の保護基を表す。]で表される5-置換-N-メチル-2-ニトロアニリン誘導体を、水素添加によって還元して下記一般式(I):
[式中、R1は水素原子、C1-C4アルキル基、または窒素原子の保護基を、R2は水素原子または窒素原子の保護基を表す。]で表される4-置換-N2-メチルベンゼン-1、2―ジアミン誘導体を製造し、
ついで、上記式(I)で表される4-置換-N2-メチルベンゼン-1、2―ジアミン誘導体と、{4-[(2,4-ジオキソ-1,3-チアゾリジン-5-イル)メチル]フェノキシ}酢酸とを、縮合剤の存在下で反応させるか、若しくは、上記式(I)で表される4-置換-N2-メチルベンゼン-1、2―ジアミン誘導体と、{4-[(2,4-ジオキソ-1,3-チアゾリジン-5-イル)メチル]フェノキシ}酢酸の酸塩化物または混合酸無水物とを反応させて、
下記一般式(II):
[式中、R1は水素原子、C1-C4アルキル基、または窒素原子の保護基を、R2は水素原子または窒素原子の保護基を表す。]で表される化合物を製造し、
ついで、上記式(II)を有する化合物を、酸の存在下、分子内で脱水縮合させ、必要に応じて窒素原子の保護基を脱保護することを特徴とする下記一般式(IV):
[式中R3は水素原子またはC1-C4アルキル基を表す]で表される6-置換-1-メチル-1H-ベンズイミダゾール誘導体若しくはその塩、またはこれらの水和物の製造方法。
Priority Applications (7)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN2010800536057A CN102725288A (zh) | 2009-11-26 | 2010-11-25 | 用于制造6-取代的1-甲基-1h-苯并咪唑衍生物的方法和所述方法的中间体 |
US13/511,190 US20120238759A1 (en) | 2009-11-26 | 2010-11-25 | Method for manufacturing a 6-substituted 1-methyl-1h-benzimidazole derivative and an intermediate of said method |
EP10833266A EP2505587A1 (en) | 2009-11-26 | 2010-11-25 | Method for manufacturing a 6-substituted-1-methyl-1h-benzimidazole derivative, and manufacturing intermediate from said method |
BR112012012378A BR112012012378A2 (pt) | 2009-11-26 | 2010-11-25 | método para fabricar um composto, e, composto |
CA2781800A CA2781800A1 (en) | 2009-11-26 | 2010-11-25 | Method for manufacturing a 6-substituted 1-methyl-1h-benzimidazole derivative and an intermediate of said method |
JP2011543294A JPWO2011065420A1 (ja) | 2009-11-26 | 2010-11-25 | 6−置換−1−メチル−1h−ベンズイミダゾール誘導体の製造法及びその製造中間体 |
IL220007A IL220007A0 (en) | 2009-11-26 | 2012-05-24 | Method for manufacturing a 6-substituted-1-methyl-1h-benzimidazole derivative, and intermediate produced thereby |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2009-269078 | 2009-11-26 | ||
JP2009269078 | 2009-11-26 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2011065420A1 true WO2011065420A1 (ja) | 2011-06-03 |
Family
ID=44066525
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/JP2010/071014 WO2011065420A1 (ja) | 2009-11-26 | 2010-11-25 | 6-置換-1-メチル-1h-ベンズイミダゾール誘導体の製造法及びその製造中間体 |
Country Status (10)
Country | Link |
---|---|
US (1) | US20120238759A1 (ja) |
EP (1) | EP2505587A1 (ja) |
JP (1) | JPWO2011065420A1 (ja) |
KR (1) | KR20120101017A (ja) |
CN (1) | CN102725288A (ja) |
BR (1) | BR112012012378A2 (ja) |
CA (1) | CA2781800A1 (ja) |
IL (1) | IL220007A0 (ja) |
TW (1) | TW201124411A (ja) |
WO (1) | WO2011065420A1 (ja) |
Cited By (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US8969581B2 (en) | 2013-03-14 | 2015-03-03 | Deuterx, Llc | 5-deutero-2,4-thiazolidinedione derivatives and compositions comprising and methods of using the same |
US9925175B2 (en) | 2007-09-26 | 2018-03-27 | Deuterx, Llc | Deuterium-enriched pioglitazone |
US10188639B2 (en) | 2014-01-15 | 2019-01-29 | Deuterx, Llc | Methods of treating neurological, metabolic, and other disorders using enantiopure deuterium-enriched pioglitazone |
US11319313B2 (en) | 2020-06-30 | 2022-05-03 | Poxel Sa | Crystalline forms of deuterium-enriched pioglitazone |
US11767317B1 (en) | 2020-06-30 | 2023-09-26 | Poxel Sa | Methods of synthesizing enantiopure deuterium-enriched pioglitazone |
Citations (19)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0745600A1 (en) | 1995-06-01 | 1996-12-04 | Sankyo Company Limited | Benzimidazole derivatives, their preparation and their therapeutic use |
JPH11193276A (ja) | 1997-10-08 | 1999-07-21 | Sankyo Co Ltd | 置換縮合複素環化合物 |
EP1022272A1 (en) | 1997-10-08 | 2000-07-26 | Sankyo Company Limited | Substituted fused heterocyclic compounds |
WO2000061582A1 (fr) | 1999-04-08 | 2000-10-19 | Sankyo Company, Limited | Derives imidazole condenses substitues |
JP2000351769A (ja) * | 1999-04-07 | 2000-12-19 | Sankyo Co Ltd | インスリン抵抗性改善剤 |
JP2000351779A (ja) * | 1999-04-07 | 2000-12-19 | Sankyo Co Ltd | アミン誘導体化合物 |
JP2000351777A (ja) | 1999-04-08 | 2000-12-19 | Sankyo Co Ltd | 置換縮合イミダゾール誘導体 |
JP2001072671A (ja) | 1999-06-28 | 2001-03-21 | Sankyo Co Ltd | ベンズイミダゾール化合物の合成中間体およびその製造方法 |
JP2001097954A (ja) | 1999-07-29 | 2001-04-10 | Sankyo Co Ltd | スルホキシベンズイミダゾール誘導体 |
EP1167366A1 (en) | 1999-04-07 | 2002-01-02 | Sankyo Company, Limited | Amine derivatives |
EP1191019A1 (en) | 1999-06-28 | 2002-03-27 | Sankyo Company, Limited | Intermediates for the synthesis of benzimidazole compounds and process for the preparation thereof |
WO2006035685A1 (ja) | 2004-09-28 | 2006-04-06 | Sankyo Company, Limited | 6-置換-1-メチル-1-h-ベンズイミダゾール誘導体の製造方法及びその製造中間体 |
JP2006124375A (ja) | 2004-09-28 | 2006-05-18 | Sankyo Co Ltd | 6−置換−1−メチル−1−h−ベンズイミダゾール誘導体の製造方法及びその製造中間体 |
JP2006225382A (ja) | 2005-01-24 | 2006-08-31 | Sankyo Co Ltd | チアゾリジンジオン化合物の製造方法及びその製造中間体 |
WO2007091622A1 (ja) | 2006-02-09 | 2007-08-16 | Daiichi Sankyo Company, Limited | 抗癌医薬組成物 |
EP1894929A1 (en) | 2005-01-24 | 2008-03-05 | Daiichi Sankyo Company, Limited | Process for producing thiazolidinedione compound and production intermediate thereof |
WO2008099944A1 (en) | 2007-02-08 | 2008-08-21 | Daiichi Sankyo Company, Limited | Crystalline forms of thiazolidinedione derivative and its manufacturing method |
WO2008126732A1 (ja) * | 2007-04-05 | 2008-10-23 | Daiichi Sankyo Company, Limited | 縮合二環式ヘテロアリール誘導体 |
JP2010106017A (ja) * | 2008-10-02 | 2010-05-13 | Daiichi Sankyo Co Ltd | 縮合二環式ヘテロアリール誘導体を含有する医薬 |
-
2010
- 2010-11-25 CA CA2781800A patent/CA2781800A1/en not_active Abandoned
- 2010-11-25 WO PCT/JP2010/071014 patent/WO2011065420A1/ja active Application Filing
- 2010-11-25 US US13/511,190 patent/US20120238759A1/en not_active Abandoned
- 2010-11-25 JP JP2011543294A patent/JPWO2011065420A1/ja active Pending
- 2010-11-25 KR KR1020127013402A patent/KR20120101017A/ko not_active Application Discontinuation
- 2010-11-25 EP EP10833266A patent/EP2505587A1/en not_active Withdrawn
- 2010-11-25 TW TW099140740A patent/TW201124411A/zh unknown
- 2010-11-25 CN CN2010800536057A patent/CN102725288A/zh active Pending
- 2010-11-25 BR BR112012012378A patent/BR112012012378A2/pt not_active IP Right Cessation
-
2012
- 2012-05-24 IL IL220007A patent/IL220007A0/en unknown
Patent Citations (29)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5886014A (en) | 1995-06-01 | 1999-03-23 | Sankyo Company, Limited | Benzimidazole derivatives, their preparation and their therapeutic use |
JP2976885B2 (ja) | 1995-06-01 | 1999-11-10 | 三共株式会社 | 縮合複素環化合物 |
EP0745600A1 (en) | 1995-06-01 | 1996-12-04 | Sankyo Company Limited | Benzimidazole derivatives, their preparation and their therapeutic use |
JP3488099B2 (ja) | 1997-10-08 | 2004-01-19 | 三共株式会社 | 置換縮合複素環化合物 |
JPH11193276A (ja) | 1997-10-08 | 1999-07-21 | Sankyo Co Ltd | 置換縮合複素環化合物 |
EP1022272A1 (en) | 1997-10-08 | 2000-07-26 | Sankyo Company Limited | Substituted fused heterocyclic compounds |
US6432993B1 (en) | 1997-10-08 | 2002-08-13 | Sankyo Company, Limited | Substituted fused heterocyclic compound |
JP2000351769A (ja) * | 1999-04-07 | 2000-12-19 | Sankyo Co Ltd | インスリン抵抗性改善剤 |
JP4197387B2 (ja) | 1999-04-07 | 2008-12-17 | 第一三共株式会社 | アミン誘導体化合物 |
JP2000351779A (ja) * | 1999-04-07 | 2000-12-19 | Sankyo Co Ltd | アミン誘導体化合物 |
EP1167366A1 (en) | 1999-04-07 | 2002-01-02 | Sankyo Company, Limited | Amine derivatives |
US6562849B1 (en) | 1999-04-07 | 2003-05-13 | Sankyo Company, Limited | Amine derivative compounds |
JP2000351777A (ja) | 1999-04-08 | 2000-12-19 | Sankyo Co Ltd | 置換縮合イミダゾール誘導体 |
WO2000061582A1 (fr) | 1999-04-08 | 2000-10-19 | Sankyo Company, Limited | Derives imidazole condenses substitues |
US6525220B2 (en) | 1999-06-28 | 2003-02-25 | Sankyo Company, Limited | Intermediates for the synthesis of benzimidazole derivatives and a process for the preparation thereof |
JP2001072671A (ja) | 1999-06-28 | 2001-03-21 | Sankyo Co Ltd | ベンズイミダゾール化合物の合成中間体およびその製造方法 |
EP1191019A1 (en) | 1999-06-28 | 2002-03-27 | Sankyo Company, Limited | Intermediates for the synthesis of benzimidazole compounds and process for the preparation thereof |
JP2001097954A (ja) | 1999-07-29 | 2001-04-10 | Sankyo Co Ltd | スルホキシベンズイミダゾール誘導体 |
WO2006035685A1 (ja) | 2004-09-28 | 2006-04-06 | Sankyo Company, Limited | 6-置換-1-メチル-1-h-ベンズイミダゾール誘導体の製造方法及びその製造中間体 |
JP2006124375A (ja) | 2004-09-28 | 2006-05-18 | Sankyo Co Ltd | 6−置換−1−メチル−1−h−ベンズイミダゾール誘導体の製造方法及びその製造中間体 |
EP1798216A1 (en) | 2004-09-28 | 2007-06-20 | Sankyo Company, Limited | Intermediate of 6-substituted-1-methyl-1-h-benzimidazole derivative and method for producing same |
US20090023929A1 (en) | 2004-09-28 | 2009-01-22 | Hisaki Kajino | Intermediate of 6-Substituted 1-Methyl-1-H-Benzimidazole Derivative and Method for Producing Same |
JP2006225382A (ja) | 2005-01-24 | 2006-08-31 | Sankyo Co Ltd | チアゾリジンジオン化合物の製造方法及びその製造中間体 |
EP1894929A1 (en) | 2005-01-24 | 2008-03-05 | Daiichi Sankyo Company, Limited | Process for producing thiazolidinedione compound and production intermediate thereof |
US20080103185A1 (en) | 2005-01-24 | 2008-05-01 | Daiichi Sankyo Company, Limited | Process for Producing Thiazolidinedione Compound and Production Intermediate Thereof |
WO2007091622A1 (ja) | 2006-02-09 | 2007-08-16 | Daiichi Sankyo Company, Limited | 抗癌医薬組成物 |
WO2008099944A1 (en) | 2007-02-08 | 2008-08-21 | Daiichi Sankyo Company, Limited | Crystalline forms of thiazolidinedione derivative and its manufacturing method |
WO2008126732A1 (ja) * | 2007-04-05 | 2008-10-23 | Daiichi Sankyo Company, Limited | 縮合二環式ヘテロアリール誘導体 |
JP2010106017A (ja) * | 2008-10-02 | 2010-05-13 | Daiichi Sankyo Co Ltd | 縮合二環式ヘテロアリール誘導体を含有する医薬 |
Non-Patent Citations (1)
Title |
---|
T.W. GREENE ET AL.: "Protective Groups in Organic Synthesis", JOHN WILLEY & SONS, INC |
Cited By (14)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US10576071B2 (en) | 2007-09-26 | 2020-03-03 | Poxel Sa | Deuterium-enriched pioglitazone |
US10940143B2 (en) | 2007-09-26 | 2021-03-09 | Poxel Sa | Deuterium-enriched pioglitazone |
US11918567B2 (en) | 2007-09-26 | 2024-03-05 | Poxel Sa | Deuterium-enriched pioglitazone |
US9925175B2 (en) | 2007-09-26 | 2018-03-27 | Deuterx, Llc | Deuterium-enriched pioglitazone |
US11123336B2 (en) | 2013-03-14 | 2021-09-21 | Poxel Sa | 5-deutero-2,4-thiazolidinedione derivatives and compositions comprising and methods of using the same |
US10265305B2 (en) | 2013-03-14 | 2019-04-23 | Poxel Sa | 5-deutero-2,4-thiazolidinedione derivatives and compositions comprising and methods of using the same |
US9416117B2 (en) | 2013-03-14 | 2016-08-16 | Deuterx, Llc | 5-deutero-2,4-thiazolidinedione derivatives and compositions comprising and methods of using the same |
US8969581B2 (en) | 2013-03-14 | 2015-03-03 | Deuterx, Llc | 5-deutero-2,4-thiazolidinedione derivatives and compositions comprising and methods of using the same |
US11918569B2 (en) | 2013-03-14 | 2024-03-05 | Poxel Sa | 5-deutero-2,4-thiazolidinedione derivatives and compositions comprising and methods of using the same |
US9833445B2 (en) | 2013-03-14 | 2017-12-05 | Deuterx, Llc | 5-deutero-2,4-thiazolidinedione derivatives and compositions comprising and methods of using the same |
US11141411B2 (en) | 2014-01-15 | 2021-10-12 | Poxel Sa | Methods of treating neurological, metabolic, and other disorders using enantiopure deuterium-enriched pioglitazone |
US10188639B2 (en) | 2014-01-15 | 2019-01-29 | Deuterx, Llc | Methods of treating neurological, metabolic, and other disorders using enantiopure deuterium-enriched pioglitazone |
US11319313B2 (en) | 2020-06-30 | 2022-05-03 | Poxel Sa | Crystalline forms of deuterium-enriched pioglitazone |
US11767317B1 (en) | 2020-06-30 | 2023-09-26 | Poxel Sa | Methods of synthesizing enantiopure deuterium-enriched pioglitazone |
Also Published As
Publication number | Publication date |
---|---|
CA2781800A1 (en) | 2011-06-03 |
US20120238759A1 (en) | 2012-09-20 |
CN102725288A (zh) | 2012-10-10 |
TW201124411A (en) | 2011-07-16 |
IL220007A0 (en) | 2012-07-31 |
KR20120101017A (ko) | 2012-09-12 |
JPWO2011065420A1 (ja) | 2013-04-18 |
EP2505587A1 (en) | 2012-10-03 |
BR112012012378A2 (pt) | 2019-09-24 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP6609065B2 (ja) | 1−(5−(2,4−ジフルオロフェニル)−1−((3−フルオロフェニル)スルホニル)−4−メトキシ−1h−ピロール−3−イル)−n−メチルメタンアミンの新規な酸付加塩 | |
US20200369652A1 (en) | Processes for preparation of lifitegrast and intermediates thereof | |
WO2007001385A2 (en) | Process for preparing 4,5-dihydro-pyrazolo [3,4-c] pyrid-2-ones | |
JP7215689B2 (ja) | 一連の抗ウイルス化合物の新規エナンチオマー | |
KR101414778B1 (ko) | 페닐피리미돈을 함유하는 화합물, 그 약물 조성물 및 그 제조방법과 용도 | |
AU2003257300B2 (en) | Amino benzothiazole compounds with NOS inhibitory activity | |
WO2011065420A1 (ja) | 6-置換-1-メチル-1h-ベンズイミダゾール誘導体の製造法及びその製造中間体 | |
EP2609099A2 (en) | Sitagliptin, salts and polymorphs thereof | |
KR20200108828A (ko) | 발베나진의 고상 형태 | |
JP7025411B2 (ja) | インドールカルボキサミド化合物の製造方法 | |
JP4385414B2 (ja) | アミド若しくはアミン誘導体 | |
CN106795174B (zh) | 一种抗病毒活性双氮氧杂环螺二酮哌嗪生物碱衍生物及其制备方法 | |
TWI284127B (en) | Cyclization process for substituted benzothiazole derivatives | |
EP3322704B1 (en) | Crystalline form of n-[(3-amino-3-oxetanyl)methyl]-2-(2,3-dihydro-1,1-dioxido-1,4-benzothiazepin-4(5h)-yl)-6-methyl-4-quinazolinamine for the treatment of respiratory syncytial virus (rsv) infections | |
EP3388430A1 (en) | Compound, compound for use in the treatment of a pathological condition, a pharmaceutical composition and a method for preparing said compound | |
JP2008523155A (ja) | ピリジル置換スピロ−ヒダントイン化合物およびその使用 | |
EP1212321B1 (en) | Intermediates for the production of naphthyridine-3-carboxylic acid derivatives | |
US9365526B2 (en) | Process for the preparation of dasatinib and its intermediates | |
WO2020053795A2 (en) | Process for the preparation of acalabrutinib and its intermediates | |
CA2579303A1 (en) | 2-substituted-1-deaza purine derivatives with adenosine receptor modulating activity | |
CN104418866A (zh) | Dgat1抑制剂及其制备方法和用途 | |
KR102398639B1 (ko) | 아미드 유도체의 염 및 그 제조방법 | |
US20040138232A1 (en) | Acyl derivatives of 5-(2-(4-(1,2 benzisothiazole-3-yl)-1-piperazinyl)ethyl)-6-chloro-1,3-dihydro-2h-indol-2-one having neuroleptic activity | |
EP1339719B1 (fr) | Derives de benzimidazole, leur preparation et leur application en therapeutique | |
US20210147466A1 (en) | Improved processes for the preparation of guadecitabine and intermediates thereof |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
WWE | Wipo information: entry into national phase |
Ref document number: 201080053605.7 Country of ref document: CN |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 10833266 Country of ref document: EP Kind code of ref document: A1 |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2010833266 Country of ref document: EP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2011543294 Country of ref document: JP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 1232/MUMNP/2012 Country of ref document: IN |
|
WWE | Wipo information: entry into national phase |
Ref document number: 13511190 Country of ref document: US |
|
ENP | Entry into the national phase |
Ref document number: 2781800 Country of ref document: CA Ref document number: 20127013402 Country of ref document: KR Kind code of ref document: A |
|
WWE | Wipo information: entry into national phase |
Ref document number: 220007 Country of ref document: IL |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
REG | Reference to national code |
Ref country code: BR Ref legal event code: B01A Ref document number: 112012012378 Country of ref document: BR |
|
ENP | Entry into the national phase |
Ref document number: 112012012378 Country of ref document: BR Kind code of ref document: A2 Effective date: 20120523 |